Keytruda continues to dominate, driving 50% of revenue, with new approvals and delivery methods strengthening MRK's oncology leadership. The company’s long-term outlook is also promising, with a full ...

Merck's two most important growth drivers are encountering headwinds now. While they are manageable, the company's mid-term prospects aren't strong. Merck's biggest growth drivers are cancer drug ...

TOKYO, Oct 8 (Reuters) - Toyota (7203.T), opens new tab and Sumitomo Metal Mining (5713.T), opens new tab said on Wednesday they have made advances in the development of cathode materials for ...

A top U.S. health official's call to split the measles-mumps-rubella (MMR) vaccine into separate shots sparked strong pushback from Merck & Co., Inc. (NYSE:MRK) and medical experts, who said such a ...

The Trump administration's direct investments in the metals sector has triggered a sweeping rally, with rare earths and battery metal stocks rocketing on prospects of federal backing and strategic ...

Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late ...

Two clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was ...

In late 2023, Metal Gear Solid: Master Collection Vol. 1 brought most of the early games in the franchise to modern consoles. Since then, fans have clamored for Konami to complete the collection of ...

One of the last remaining Munchkin characters from the 1939 MGM classic “Wizard of Oz” has died. Elaine Merk Binder, who performed as one of the film’s merry little people when she was 8 years old, ...

Elaine Merk Binder, one of the last surviving actors who played a Munchkin in the 1939 classic “The Wizard of Oz,” has died, according to her daughter Annette Phillips. She was 94. Binder auditioned ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.